Stock A131030 OPTUS PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials OPTUS Pharmaceutical Co., Ltd.

Equities

A131030

KR7131030009

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-03 pm EDT 		5-day change 1st Jan Change
6,130 KRW -0.33% Intraday chart for OPTUS Pharmaceutical Co., Ltd. +2.00% +15.23%
2023 OPTUS Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2022 Tranche Update on OPTUS Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 7, 2022. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 143,451 128,046 138,482 112,144 101,603 85,935
Enterprise Value (EV) 1 84,283 59,064 56,547 37,829 42,647 19,485
P/E ratio 14.1 x 8.65 x 9.36 x 11 x 19.9 x 7.51 x
Yield - - - - - -
Capitalization / Revenue 2.89 x 2.12 x 2.28 x 1.96 x 1.73 x 1.19 x
EV / Revenue 1.7 x 0.98 x 0.93 x 0.66 x 0.73 x 0.27 x
EV / EBITDA 6.07 x 3.32 x 3.25 x 2.93 x 4.9 x 1.57 x
EV / FCF 7.92 x 26.7 x 4.25 x -8.87 x -8.7 x 3.34 x
FCF Yield 12.6% 3.75% 23.5% -11.3% -11.5% 30%
Price to Book 1.49 x 1.17 x 1.13 x 0.85 x 0.77 x 0.6 x
Nbr of stocks (in thousands) 16,565 16,565 16,565 16,565 16,153 16,153
Reference price 2 8,660 7,730 8,360 6,770 6,290 5,320
Announcement Date 3/1/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 49,625 60,441 60,827 57,316 58,658 72,426
EBITDA 1 13,874 17,809 17,392 12,895 8,712 12,424
EBIT 1 10,715 15,189 14,808 10,472 5,249 8,187
Operating Margin 21.59% 25.13% 24.34% 18.27% 8.95% 11.3%
Earnings before Tax (EBT) 1 11,280 16,421 18,502 10,479 6,828 12,970
Net income 1 10,003 14,596 14,405 9,892 5,012 10,760
Net margin 20.16% 24.15% 23.68% 17.26% 8.54% 14.86%
EPS 2 612.7 894.1 892.8 616.6 315.8 708.3
Free Cash Flow 1 10,641 2,212 13,314 -4,264 -4,902 5,838
FCF margin 21.44% 3.66% 21.89% -7.44% -8.36% 8.06%
FCF Conversion (EBITDA) 76.7% 12.42% 76.55% - - 46.99%
FCF Conversion (Net income) 106.38% 15.16% 92.43% - - 54.25%
Dividend per Share - - - - - -
Announcement Date 3/1/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 59,168 68,982 81,935 74,315 58,956 66,450
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 10,641 2,212 13,314 -4,264 -4,902 5,838
ROE (net income / shareholders' equity) 11% 14.4% 12.7% 8.05% 3.99% 8.31%
ROA (Net income/ Total Assets) 6.75% 8.52% 7.44% 4.85% 2.37% 3.58%
Assets 1 148,222 171,343 193,681 203,982 211,040 300,418
Book Value Per Share 2 5,813 6,600 7,411 7,918 8,207 8,811
Cash Flow per Share 2 2,075 2,154 2,645 2,029 686.0 1,167
Capex 1 689 3,805 5,842 10,628 6,001 3,329
Capex / Sales 1.39% 6.3% 9.6% 18.54% 10.23% 4.6%
Announcement Date 3/1/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
OPTUS PHARMACEUTICAL CO., LTD. Stock OPTUS Pharmaceutical Co., Ltd.
+15.23% 72.42M
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+14.26% 9.15B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-13.94% 4.9B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+48.58% 4.46B
YUHAN CORPORATION Stock Yuhan Corporation
+14.10% 4.09B
INDIVIOR PLC Stock Indivior PLC
+19.66% 2.49B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-25.55% 2.17B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+18.39% 2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-39.57% 1.89B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A131030 Stock
  4. Financials OPTUS Pharmaceutical Co., Ltd.